Advertisement
Canada markets open in 4 hours 15 minutes
  • S&P/TSX

    21,953.80
    +78.01 (+0.36%)
     
  • S&P 500

    5,509.01
    +33.92 (+0.62%)
     
  • DOW

    39,331.85
    +162.33 (+0.41%)
     
  • CAD/USD

    0.7312
    +0.0001 (+0.02%)
     
  • CRUDE OIL

    83.02
    +0.21 (+0.25%)
     
  • Bitcoin CAD

    82,793.59
    -2,835.30 (-3.31%)
     
  • CMC Crypto 200

    1,304.59
    -30.33 (-2.27%)
     
  • GOLD FUTURES

    2,353.50
    +20.10 (+0.86%)
     
  • RUSSELL 2000

    2,033.87
    +3.81 (+0.19%)
     
  • 10-Yr Bond

    4.4360
    -0.0430 (-0.96%)
     
  • NASDAQ futures

    20,265.50
    +10.25 (+0.05%)
     
  • VOLATILITY

    12.13
    +0.10 (+0.83%)
     
  • FTSE

    8,162.25
    +41.05 (+0.51%)
     
  • NIKKEI 225

    40,580.76
    +506.07 (+1.26%)
     
  • CAD/EUR

    0.6793
    -0.0007 (-0.10%)
     

Stocks in play: Oncolytics Biotech Inc

Today announced the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer. The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint. The Company's proposed study will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate therapy. Oncolytics Biotech Inc shares T.ONC are trading unchanged at $1.42.

Read: